Effect of piroxicam on the blood-retina barrier in experimentally induced diabetes in rats
โ Scribed by Mostafa Bahgat; Hossam H. Anis; Gholam A. Peyman; Hassan G. Farahat; Gareth J. Parry; Bahram Khoobehi
- Publisher
- Springer Netherlands
- Year
- 1991
- Tongue
- English
- Weight
- 510 KB
- Volume
- 15
- Category
- Article
- ISSN
- 0165-5701
No coin nor oath required. For personal study only.
โฆ Synopsis
The effect of piroxicam on the blood-retina barrier was evaluated in rats with experimentally induced diabetes. Diabetes was induced in rats by intraperitoneal injection of streptozocin (STZ). Diabetic rats were divided into two equal groups: those treated with piroxicam, a long-acting platelet inhibitor, and an untreated control group. Vitreous fluorophotometry (VFP) was performed both before and two weeks after induction of diabetes and piroxicam intake. Streptozocin-induced diabetes caused an alteration in the blood-retinal barrier evidenced by an increase in vitreous fluorescein concentration in diabetic rats compared with normal rats. Piroxicam intake did not lead to significant change in vitreous fluorescein concentrations. However, the examination had to be terminated at two weeks because of cataract formation. The piroxicam treated group showed less incidence of lens opacity formation (59.1% compared to 81.8% in the untreated group, p = 0.0006). Piroxicam administration appears to protect the diabetic rat eye against lens opacification.
๐ SIMILAR VOLUMES
There is considerable evidence that phosphatidate (PA) and Iysophosphatidate (LPA) are important second messengers in sisnal transduotion processes in a variety of nell types. Objecti~s It. To determine the ability of PA and LPA to serve as substrates for the placental, intestinal and tissue nonspee
The effect of calcium dobesilate on the alteration of the blood-retinal barrier was studied in 41 adult-onset, non-insulin dependent diabetic patients with minimal or no retinopathy, randomly assigned to receive either oral calcium dobesilate (1000 mg twice daily) or a placebo for 12 months. The pos